Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical (LFCR) Gross Margin: 2009-2025

Historic Gross Margin for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to 38.37%.

  • Lifecore Biomedical's Gross Margin fell 722.00% to 38.37% in Q2 2025 from the same period last year, while for May 2025 it was 31.27%, marking a year-over-year decrease of 136.00%. This contributed to the annual value of 31.27% for FY2025, which is 136.00% down from last year.
  • Latest data reveals that Lifecore Biomedical reported Gross Margin of 38.37% as of Q2 2025, which was up 36.99% from 28.01% recorded in Q1 2025.
  • Lifecore Biomedical's 5-year Gross Margin high stood at 45.59% for Q2 2024, and its period low was 11.12% during Q3 2023.
  • Moreover, its 3-year median value for Gross Margin was 32.62% (2023), whereas its average is 30.25%.
  • As far as peak fluctuations go, Lifecore Biomedical's Gross Margin skyrocketed by 2,620bps in 2021, and later plummeted by 1,878bps in 2022.
  • Lifecore Biomedical's Gross Margin (Quarterly) stood at 44.76% in 2021, then plummeted by 1,878bps to 25.97% in 2022, then surged by 705bps to 33.02% in 2023, then soared by 101bps to 34.04% in 2024, then tumbled by 722bps to 38.37% in 2025.
  • Its Gross Margin was 38.37% in Q2 2025, compared to 28.01% in Q1 2025 and 34.04% in Q4 2024.